Comprehensive Glioma Panel

What is Comprehensive Glioma Panel test?

A Comprehensive Glioma Panel test uses NGS to assess mutations, CNVs, and fusions across 161 glioma‑linked genes while evaluating MGMT promoter methylation. The panel captures core drivers and integrates these findings for precise classification.

Why consider Comprehensive Glioma Panel test?

• Enables comprehensive molecular profiling from limited tissue, detecting SNVs/indels, CNVs, and fusions that refine diagnosis and reveal actionable alterations for targeted therapies and clinical trials in a single workflow with faster turnaround than sequential tests.
• MGMT promoter methylation status provides prognostic and predictive value for temozolomide benefit in glioblastoma and other high‑grade gliomas, aiding treatment planning alongside radiotherapy decisions.

Who should get tested for Comprehensive Glioma Panel test?

• Patients with newly diagnosed diffuse gliomas or glioblastoma where integrated histo‑molecular classification and treatment planning are required at baseline resection/biopsy.
• Patients with recurrent or progressive gliomas to uncover resistance mechanisms, new targets, or eligibility for precision‑medicine trials, especially when prior profiling was limited or outdated.

More Information about Comprehensive Glioma Panel test

OTHER NAMES: Comprehensive Glioma NGS Panel with MGMT Methylation, Advanced/Expanded Glioma Panel (multi‑gene NGS + MGMT promoter methylation)

Glioma is a primary tumor of glial cells in the brain and spinal cord, now classified primarily by molecular markers alongside histology, especially IDH mutation status and 1p/19q codeletion in adults. Modern classification separates adult diffuse gliomas into IDH‑mutant astrocytoma, IDH‑mutant and 1p/19q‑codeleted oligodendroglioma, and IDH‑wildtype glioblastoma, which differ in prognosis and therapy response.